Global Strongyloidiasis Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Strongyloidiasis Treatment Market Size

• The global strongyloidiasis treatment market size was valued at USD 1.60 billion in 2024 and is expected to reach USD 2.22 billion by 2032, at a CAGR of 4.20% during the forecast period
• The market growth is largely fueled by the increasing prevalence of strongyloidiasis, particularly in tropical and subtropical regions, along with enhanced awareness and improved diagnostic capabilities
• Furthermore, rising demand for effective, accessible, and well-tolerated treatment options is establishing ivermectin and other therapies as the standard of care, accelerating the uptake of strongyloidiasis treatment solutions, thereby significantly boosting the industry's growth

Strongyloidiasis Treatment Market Analysis

• Strongyloidiasis treatments, including pharmacological therapies such as ivermectin, albendazole, and mebendazole, are increasingly vital components of parasitic infection management in both endemic and non-endemic regions due to their proven efficacy, safety profile, and widespread adoption in healthcare systems
• The escalating demand for strongyloidiasis treatment is primarily fueled by the rising prevalence of the disease, improved diagnostic capabilities, and increasing awareness among healthcare providers and communities, alongside government and NGO initiatives to expand treatment access in tropical and subtropical regions
• North America dominated the strongyloidiasis treatment market with the largest revenue share of 38.9% in 2024, characterized by advanced healthcare infrastructure, strong adoption of first-line therapies, and a well-established network of hospitals and clinics providing diagnosis and treatment, with the U.S. showing significant growth in both chronic and acute strongyloidiasis management
• Asia-Pacific is expected to be the fastest-growing region in the strongyloidiasis treatment market during the forecast period due to improving healthcare infrastructure, rising awareness programs, and government-led parasitic infection control initiatives in countries such as India, Indonesia, and the Philippines
• Chronic strongyloidiasis segment dominated the strongyloidiasis treatment market in 2024 with a share of 62.5%, driven by higher prevalence, the need for long-term management, and established treatment protocols using first-line therapies like ivermectin

Report Scope and Strongyloidiasis Treatment Market Segmentation 

Strongyloidiasis Treatment Market Trends

Advancements in Diagnostic and Treatment Technologies

• A significant and accelerating trend in the global strongyloidiasis treatment market is the adoption of advanced diagnostic tools and treatment methods, including blood antigen tests, stool tests, and more precise first-line therapies, which are enhancing early detection and improving patient outcomes
  • For instance, the Duodenal Aspiration Test allows clinicians to detect Strongyloides stercoralis infections with higher accuracy, leading to timely intervention and reduced risk of chronic complications
• Integration of digital health tools and telemedicine platforms is enabling better monitoring of patient treatment compliance and follow-up, especially in remote or endemic regions
• These technological advancements facilitate centralized patient management, allowing healthcare providers to track diagnostics, treatment progress, and adverse events through a unified system
• This trend towards more efficient, precise, and patient-centric approaches is fundamentally reshaping treatment standards, with companies and healthcare providers focusing on improving accessibility and accuracy of strongyloidiasis management
• The demand for advanced diagnostic and treatment technologies is growing rapidly across both endemic and non-endemic regions, as healthcare systems prioritize timely intervention and effective disease management

Strongyloidiasis Treatment Market Dynamics

Driver

Rising Disease Prevalence and Awareness Programs

• The increasing prevalence of strongyloidiasis in tropical and subtropical regions, coupled with awareness programs by governments and NGOs, is a significant driver for the heightened demand for effective treatments
  • For instance, mass drug administration initiatives in Latin America and Sub-Saharan Africa have led to greater treatment coverage and higher adoption of first-line therapies like ivermectin
• As healthcare providers and communities become more aware of parasitic infection risks, early diagnosis and treatment have become critical to preventing severe chronic cases
• Furthermore, increased availability of effective therapies and improved healthcare infrastructure are making treatment more accessible across hospitals, clinics, and pharmacies
• The convenience of first-line therapy regimens, shorter treatment durations, and clear clinical guidelines are key factors propelling adoption in both endemic and non-endemic regions, while ongoing awareness campaigns further enhance market growth

Restraint/Challenge

Drug Resistance and Limited Healthcare Access

• Concerns surrounding emerging drug resistance, adverse effects, and inconsistent treatment adherence pose significant challenges to broader market penetration of strongyloidiasis therapies
  • For instance, reported cases of partial treatment failure with albendazole in some regions have raised concerns about long-term efficacy and prompted the need for alternative or combination therapies
• Limited access to healthcare facilities and diagnostic services in remote or underserved endemic areas restricts timely detection and treatment of the infection
• Overcoming these challenges through enhanced drug development, training of healthcare workers, and expansion of diagnostic and treatment infrastructure is critical for sustained market growth
• Additionally, variability in treatment guidelines and limited awareness among certain populations can hinder adoption, particularly in rural communities where healthcare resources are scarce
• Ensuring consistent supply of antiparasitic drugs, coupled with education and outreach programs, is vital to mitigate these challenges and expand market reach

Strongyloidiasis Treatment Market Scope

The market is segmented on the basis of type, diagnosis tests, treatment type, drug class, end users, and distribution channel.

• By Type

On the basis of type, the strongyloidiasis treatment market is segmented into acute strongyloidiasis and chronic strongyloidiasis. The chronic strongyloidiasis segment dominated the market with a share of 62.5% in 2024, driven by the higher prevalence of chronic infections and the need for long-term management using first-line therapies such as ivermectin. Chronic infections require careful monitoring and follow-up to prevent severe complications, making established treatments essential in endemic regions. The dominance is further supported by clinical guidelines emphasizing early and sustained intervention. Hospitals and clinics prioritize chronic cases due to their higher risk of morbidity, and awareness programs by NGOs and governments enhance market penetration. Treatment accessibility and patient adherence programs also contribute to chronic strongyloidiasis maintaining market leadership.

The acute strongyloidiasis segment is expected to witness the fastest growth from 2025 to 2032, fueled by increasing early diagnosis through improved detection methods and heightened awareness. Prompt treatment of acute cases reduces progression to chronic infections and associated complications. Expansion of telemedicine and community health programs enables rapid intervention even in remote areas. Pharmaceutical companies are developing shorter and effective therapy regimens for acute cases to improve compliance. Increasing government and NGO initiatives targeting acute infections are further driving adoption. The growing prevalence in non-endemic regions due to travel and migration also contributes to market growth.

• By Diagnosis Tests

On the basis of diagnosis, the strongyloidiasis treatment market is segmented into duodenal aspiration test, sputum culture test, stool test, complete blood count (CBC) test, and blood antigen test. The stool test segment dominated in 2024 due to its simplicity, low cost, and wide adoption in hospitals and clinics. Stool tests allow routine screening, early detection, and timely treatment, which are critical for both acute and chronic infections. The high reliability and minimal invasiveness of stool tests make them preferred diagnostic tools. Technological improvements in sample analysis and reporting increase accuracy. Stool tests are supported by public health initiatives for mass screening. Widespread clinician familiarity also contributes to its dominance in endemic regions.

The blood antigen test segment is expected to witness the fastest growth during the forecast period due to its high sensitivity and suitability for detecting low-intensity infections. Blood antigen tests allow early identification before symptoms develop, supporting proactive treatment strategies. Increasing availability in hospitals and specialized clinics drives adoption. Technological advances in immunoassays improve reliability and turnaround time. Mass screening programs supported by NGOs and governments also expand usage. Growing awareness among healthcare providers about early detection benefits fuels market expansion.

• By Treatment Type

On the basis of treatment type, the strongyloidiasis treatment market is segmented into first-line therapy and second-line therapy. The first-line therapy segment dominated in 2024, driven by the widespread use of ivermectin as the gold standard, recognized for high efficacy and inclusion in WHO guidelines. First-line therapy ensures rapid parasite clearance and is widely available in hospitals, clinics, and pharmacies. Global treatment programs and NGO initiatives prioritize first-line treatment to reduce disease burden. Established clinical protocols support its dominance in both acute and chronic infections. Patient compliance and successful outcomes reinforce its market leadership. Continued supply chain stability ensures accessibility in endemic regions.

The second-line therapy segment is expected to witness the fastest growth from 2025 to 2032 due to increasing cases of drug resistance, treatment failures, and the need for alternative regimens. Second-line therapies, including albendazole and mebendazole, are used in patients intolerant to first-line drugs. Combination therapy approaches and new formulations are expanding adoption. Growing awareness among healthcare providers about alternative protocols is driving usage. NGOs and public health programs are supporting second-line therapy in regions with emerging resistance. Expanding availability in hospitals and pharmacies also contributes to rapid growth.

• By Drug Class

On the basis of drug class, the strongyloidiasis treatment market is segmented into antiparasitic drugs and others. The antiparasitic drugs segment dominated in 2024 due to the critical role of ivermectin, albendazole, and mebendazole in effectively treating infections. These drugs are widely accepted, accessible, and incorporated into clinical guidelines. Public health programs and large-scale treatment initiatives in endemic regions further reinforce market dominance. Hospitals and clinics rely on antiparasitic drugs for both acute and chronic infections. High efficacy and predictable outcomes maintain preference among healthcare providers. Continuous supply and awareness campaigns strengthen adoption globally.

The others segment is expected to witness the fastest growth during the forecast period due to increasing development of supportive therapies that manage symptoms, improve patient adherence, and complement antiparasitic treatments. Novel formulations and combination therapies enhance efficacy and reduce treatment duration. Adoption in specialized clinics and hospitals is rising. Clinical trials and research initiatives are driving innovation. Supportive care medications improve patient outcomes in complex cases. The growth is fueled by healthcare initiatives promoting comprehensive treatment approaches.

• By End Users

On the basis of end users, the strongyloidiasis treatment market is segmented into clinics, hospitals, and others. The hospitals segment dominated the market in 2024, owing to better diagnostic facilities, availability of specialized treatments, and higher patient inflow for severe and chronic cases. Hospitals offer integrated care, including treatment administration, monitoring, and follow-up. Large-scale awareness campaigns target hospital-based care for effective disease management. Hospitals are central to first-line therapy distribution and compliance monitoring. Specialized hospital staff ensure accurate diagnosis and treatment. Their infrastructure supports both inpatient and outpatient treatment, reinforcing dominance.

The clinics segment is expected to witness the fastest growth during the forecast period due to expanding primary healthcare networks and community health outreach programs. Clinics play a vital role in early diagnosis and management of mild to moderate infections. Telemedicine integration allows clinics to provide remote follow-up and guidance. Growing awareness in rural and semi-urban areas drives adoption. Clinics are increasingly stocking first-line and second-line therapies to improve access. NGO and government programs supporting community-level treatment enhance growth opportunities.

• By Distribution Channel

On the basis of distribution channel, the strongyloidiasis treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. The hospital pharmacy segment dominated the market in 2024 due to direct access to first-line therapies, strong linkages with healthcare providers, and established procurement systems. Hospital pharmacies ensure timely availability for both acute and chronic cases. Centralized distribution supports large-scale treatment initiatives. Hospitals rely on in-house pharmacies for immediate patient care. Procurement systems in endemic regions maintain uninterrupted drug supply. Hospital pharmacies also provide guidance on proper usage and dosage.

The online pharmacy segment is expected to witness the fastest growth from 2025 to 2032, fueled by increasing digitalization, expansion of telemedicine, and growing consumer comfort with online ordering. Online pharmacies improve access to antiparasitic drugs in remote and underserved areas. They enable timely delivery, supporting treatment adherence. Growth in smartphone penetration and e-health platforms enhances convenience. Digital ordering systems allow secure, trackable distribution. NGOs and public health initiatives are leveraging online channels to expand reach.

Strongyloidiasis Treatment Market Regional Analysis

• North America dominated the strongyloidiasis treatment market with the largest revenue share of 38.9% in 2024, characterized by advanced healthcare infrastructure, strong adoption of first-line therapies, and a well-established network of hospitals and clinics providing diagnosis and treatment
• Patients and healthcare providers in the region prioritize early detection and effective treatment using first-line therapies such as ivermectin, supported by robust diagnostic facilities including stool tests, blood antigen tests, and duodenal aspiration tests
• The widespread adoption of advanced treatment protocols is further supported by strong government and NGO initiatives, high healthcare spending, and increased accessibility to hospital and clinic-based services, establishing effective strongyloidiasis management as a standard in both endemic and non-endemic areas

U.S. Strongyloidiasis Treatment Market Insight

The U.S. strongyloidiasis treatment market captured the largest revenue share of 82% in North America in 2024, driven by advanced healthcare infrastructure, high awareness among healthcare providers, and strong adoption of first-line therapies such as ivermectin. Patients and clinicians prioritize early detection using stool tests, blood antigen tests, and duodenal aspiration tests, enabling prompt and effective treatment. The growth is further fueled by government and NGO programs focusing on parasitic disease management, particularly in at-risk populations. Increased access to hospital and clinic-based care, alongside telemedicine initiatives, enhances treatment coverage. Rising awareness of chronic strongyloidiasis and preventive strategies supports market expansion. The U.S. also benefits from ongoing research and innovation in diagnostics and therapeutics, reinforcing its market leadership.

Europe Strongyloidiasis Treatment Market Insight

The Europe strongyloidiasis treatment market is projected to expand at a substantial CAGR during the forecast period, primarily driven by improved diagnostic infrastructure, rising awareness of parasitic infections, and increasing healthcare spending. Stringent health regulations and government-led initiatives to control neglected tropical diseases are accelerating treatment adoption. Hospitals and clinics across Europe are increasingly equipped with advanced diagnostic tools such as stool tests, CBC, and blood antigen tests, enabling early intervention. The demand is further supported by NGO programs targeting vulnerable populations. Urbanization and growing access to modern healthcare facilities are encouraging timely treatment. Additionally, public health campaigns focusing on chronic strongyloidiasis are contributing to market growth.

U.K. Strongyloidiasis Treatment Market Insight

The U.K. strongyloidiasis treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness of parasitic infections and the adoption of advanced first-line therapies. Concerns regarding infection risks in immunocompromised and traveling populations are prompting both hospitals and clinics to implement early detection and treatment protocols. Integration of diagnostic tools, including stool tests and blood antigen tests, is supporting rapid and accurate management. Public health programs and NGO initiatives are increasing outreach to high-risk groups. The growing prevalence of chronic cases emphasizes the need for sustained therapy and monitoring. Availability of healthcare infrastructure and strong pharmacy networks further stimulate market growth.

Germany Strongyloidiasis Treatment Market Insight

The Germany strongyloidiasis treatment market is expected to expand at a considerable CAGR during the forecast period, fueled by rising awareness of parasitic diseases, robust healthcare infrastructure, and strong emphasis on preventive care. Hospitals and specialized clinics are adopting advanced diagnostics such as duodenal aspiration and blood antigen tests to ensure timely treatment. Chronic strongyloidiasis cases receive focused attention due to potential severe complications, increasing demand for first-line therapies. Government health programs and research initiatives are promoting treatment accessibility. Patient education and training of healthcare providers are enhancing disease management efficiency. The market growth is supported by Germany’s emphasis on sustainable and technologically advanced healthcare solutions.

Asia-Pacific Strongyloidiasis Treatment Market Insight

The Asia-Pacific strongyloidiasis treatment market is poised to grow at the fastest CAGR from 2025 to 2032, driven by high disease prevalence, increasing healthcare infrastructure, and rising awareness in countries such as India, China, and Japan. Government initiatives and NGO programs are expanding access to first-line therapies in endemic regions. Rapid urbanization and increasing disposable incomes are improving healthcare-seeking behavior. Technological advancements in diagnostics, including stool tests and blood antigen tests, are enhancing early detection and treatment coverage. Availability of affordable therapies and expansion of hospital and clinic networks support rapid market adoption. Collaboration with international health organizations is also driving regional growth.

Japan Strongyloidiasis Treatment Market Insight

The Japan strongyloidiasis treatment market is gaining momentum due to rising awareness of parasitic infections, demand for preventive healthcare, and advanced diagnostic capabilities. The growing number of hospitals and specialized clinics with access to stool tests, CBC, and blood antigen tests ensures timely detection and treatment of both acute and chronic cases. Telemedicine and digital health initiatives are supporting patient follow-up and treatment adherence. Public health programs targeting at-risk populations are contributing to increased adoption of first-line therapies. Japan’s aging population is driving demand for easier-to-administer, effective treatment options. Integration of treatment protocols with broader healthcare services is enhancing market efficiency.

India Strongyloidiasis Treatment Market Insight

The India strongyloidiasis treatment market accounted for the largest revenue share in Asia-Pacific in 2024, attributed to the high prevalence of the infection, expanding healthcare access, and increasing awareness among communities and healthcare providers. Government initiatives, including mass drug administration programs, are enhancing first-line therapy adoption. Availability of affordable antiparasitic drugs in hospitals, clinics, and retail pharmacies further supports growth. Rapid urbanization and improvements in healthcare infrastructure are increasing early diagnosis and treatment rates. NGO programs targeting endemic regions are increasing outreach and education. The presence of strong domestic pharmaceutical manufacturers ensures steady supply and availability of treatments across the country.

Strongyloidiasis Treatment Market Share

The Strongyloidiasis Treatment industry is primarily led by well-established companies, including:

• Merck & Co., Inc. (U.S.)
• Cipla (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Abbott (U.S.)
• Bayer AG (Germany)
• Glenmark Pharmaceuticals Ltd. (India)
• Sanofi (France)
• Boehringer Ingelheim (Germany)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Aurobindo Pharma Ltd. (India)
• Lupin (India)
• Dr. Reddy’s Laboratories (India)
• Eisai Co., Ltd. (Japan)
• Teva Pharmaceuticals (Israel)
• Johnson & Johnson and its affiliates (U.S.)
• Edenbridge Pharmaceuticals (U.S.)
• Hikma Pharmaceuticals (U.K.)
• Sandoz International GmbH (Switzerland)

What are the Recent Developments in Global Strongyloidiasis Treatment Market?

• In May 2025, Scientists at the Liverpool School of Tropical Medicine developed a more precise diagnostic tool to distinguish between two closely related threadworm species, enhancing global surveillance and detection of strongyloidiasis
• In May 2025, A study conducted in Ethiopia found a 90% cure rate for strongyloidiasis using a two- day regimen of ivermectin (200 μg/kg), supporting its efficacy and the current treatment strategy in the region
• In April 2025, Research published in The Lancet demonstrated that moxidectin is non-inferior to ivermectin in treating chronic strongyloidiasis, with similar safety profiles, offering a potential alternative treatment option
• In February 2025, The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the combination of ivermectin and albendazole for treating various parasitic worm infections, including strongyloidiasis, enhancing treatment options in endemic regions
• In August 2024, The World Health Organization (WHO) issued its first guideline on the public health control of strongyloidiasis, recommending mass drug administration with single-dose ivermectin (200 μg/kg) in endemic settings with a prevalence of 5% or higher. This marks a significant step toward integrating strongyloidiasis control into public health strategies

SKU-59433